HBV-siRNA encapsulated in Nano- lipid Particle Delivery Platform (NPDP) for the treatment of chronic hepatitis B (CHB).

Features of  Kylo-02:

※  Interrupt  the replication cycle of the viruses

—      Reduces the production of new virus particles in the circulation by degrading all RNA from the virus

—      Enhanced therapeutic effect with NUC drugs

—      Enhanced immunological response to HBV viruseswith Interferon 

※  Reduce immune tolerance in the body

—      Inhibit HBsAg

—      Inhibit HBeAg

※  Recovering immune response against HBV

—      Enhance the antiviral function of RNAi in return

※ Functional cure

—      Achieve HBsAg clearance and conversion

—     Prevent further deterioration of the disease to cirrhosis and liver cancer

—     Clear viral DNA from the blood and restore liver function

Comparison the effectof kylo-02 with the listed nucleoside (NUC) on HBV: 

Currently available anti-HBV drugs at home and abroad include Interferon and nucleos(t)ide, such as Lamivudine, Adefovir Dipivoxil, Entecavir, Tenofovir and Telbivudine. The above drugs can only alleviate the symptoms and temporarily inhibit the virus. The amount of virus will rebound if medication is stopped so that lifelong medication is required. There are currently no means or drugs to cure hepatitis B virus infection worldwide. Moreover, current treatments have led to resistant strains, and there are no drugs against drug-resistant strains or drugs that prevent transmission.

Research Progress: